ArticleBMC cancer2025
Efficacy and safety of DEB-TACE combined with HAIC and donafenib in the treatment of unresectable hepatocellular carcinoma: a dual-center retrospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DEB-TACE-HAIC combined with donafenib and camrelizumab in the treatment of unresectable hepatocellular carcinoma: a multicenter retrospective study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis retrospective study aimed to evaluate the safety and efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with hepatic arterial infusion chemotherapy (HAIC) and donafenib in the treatment of unresectable hepatocellular carcinoma (uHCC). MATERIALS AND
methodsThis dual-center retrospective study collected and analyzed clinical data from 87 patients with unresectable hepatocellular carcinoma (uHCC) who received either DEB-TACE combined with HAIC and donafenib or DEB-TACE combined with donafenib between November 2022 and December 2023 at two hospitals in China. Patients were stratified into two groups based on whether HAIC was administered: the DEB-TACE + H + D group and the DEB-TACE + D group. Treatment efficacy was evaluated using objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Prognostic factors for PFS and OS were assessed using Cox proportional hazards regression models. Treatment safety was evaluated by the incidence and severity of adverse events (AEs).
resultsIn terms of treatment efficacy, the DEB-TACE + H + D group showed significantly higher objective response rate (ORR; 69.0% vs. 44.4%, P = 0.021) compared with the DEB-TACE + D group. Moreover, the disease control rate (DCR) in the DEB-TACE + H + D group was higher than that in the DEB-TACE + D group (90.5% vs. 73.3%, P = 0.039).The median progression-free survival (PFS) was significantly longer in the DEB-TACE + H + D group than in the DEB-TACE + D group (9.00 months vs. 7.00 months, P = 0.0078), as was the median overall survival (OS) (19.00 months vs. 13.00 months, P = 0.0031).Cox regression analysis identified treatment method as the only independent prognostic factors for PFS, while tumor diameter, BCLC staging, and treatment method were independent predictors of OS. Regarding safety, there were no significant differences between the two groups in the incidence or severity of adverse events (AEs) (P > 0.05), and most AEs were mild to moderate in intensity.
conclusionCompared with DEB-TACE combined with donafenib, the combination of DEB-TACE, HAIC, and donafenib demonstrated superior tumor control and survival benefit in patients with uHCC, with an acceptable safety profile. Further prospective randomized controlled trials are warranted to validate the long-term efficacy and safety of this combination strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.